Wells Fargo raised the firm’s price target on Celldex to $27 from $21 and keeps an Underweight rating on the shares. Both barzo’s CSU and PN data look good, as the firm expected. Looking ahead, the company will need to raise a significant amount of cash, faces competitor headwinds and has few catalysts, Wells argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLDX:
- Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
- Celldex Therapeutics Announces Proposed Public Offering of Common Stock
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Celldex price target raised to $80 from $73 at H.C. Wainwright
- Celldex’s barzolvolimab meets primary endpoint in Phase 2 urticaria study